ROR1 targeted immunoliposomal delivery of OSU-2S shows selective cytotoxicity in t(1;19)(q23;p13) translocated B-cell acute lymphoblastic leukemia.
作者信息
Goswami Swagata, Chiang Chi-Ling, Zapolnik Kevan, Nunes Jessica, Ventura Ann, Mo Xiaokui, Xie Zhiliang, Lee L James, Baskar Sivasubramanian, Rader Christoph, Byrd John C, Phelps Mitch, Bhatnagar Bhavana, Muthusamy Natarajan
机构信息
Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA; Molecular, Cellular and Developmental Biology Graduate Program, The Ohio State University, Columbus, OH, USA.
Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
出版信息
Leuk Res. 2022 Jul;118:106872. doi: 10.1016/j.leukres.2022.106872. Epub 2022 May 24.
Abstract
摘要
相似文献
1
ROR1 targeted immunoliposomal delivery of OSU-2S shows selective cytotoxicity in t(1;19)(q23;p13) translocated B-cell acute lymphoblastic leukemia.ROR1靶向的OSU-2S免疫脂质体递送在t(1;19)(q23;p13)易位的B细胞急性淋巴细胞白血病中显示出选择性细胞毒性。
Leuk Res. 2022 Jul;118:106872. doi: 10.1016/j.leukres.2022.106872. Epub 2022 May 24.
2
Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia.肿瘤抗原ROR1靶向药物递送介导慢性淋巴细胞白血病中白血病B细胞而非正常B细胞的选择性细胞毒性。
Leukemia. 2015 Feb;29(2):346-55. doi: 10.1038/leu.2014.199. Epub 2014 Jun 20.
3
ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo.OSU-2S是一种非免疫抑制性的FTY720衍生物，其靶向ROR1递送在体外和体内对套细胞淋巴瘤均具有强大的细胞毒性。
Exp Hematol. 2015 Sep;43(9):770-4.e2. doi: 10.1016/j.exphem.2015.04.008. Epub 2015 Apr 29.
4
ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia.ROR1 在造血前体细胞（非肿瘤性人类 B 淋巴细胞前体）和少数前体 B 急性淋巴细胞白血病中表达。
Leuk Res. 2011 Oct;35(10):1390-4. doi: 10.1016/j.leukres.2011.06.021. Epub 2011 Aug 2.
5
Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting.Wnt5a 和 ROR1 通过 RhoA 在 TCF3-PBX1 急性淋巴细胞白血病中激活非经典 Wnt 信号通路，并通过 Bcl-2 联合靶向作用突显新的治疗策略。
Oncogene. 2019 Apr;38(17):3288-3300. doi: 10.1038/s41388-018-0670-9. Epub 2019 Jan 10.
6
Detection of orphan receptor tyrosine kinase (ROR-1) expression in Egyptian pediatric acute lymphoblastic leukemia.埃及儿童急性淋巴细胞白血病中孤儿受体酪氨酸激酶（ROR-1）表达的检测
Fetal Pediatr Pathol. 2012 Jun;31(3):113-9. doi: 10.3109/15513815.2012.656825. Epub 2012 Feb 27.
7
Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia.ROR1 与前 B 细胞受体的串扰促进 t(1;19) 急性淋巴细胞白血病的存活。
Cancer Cell. 2012 Nov 13;22(5):656-67. doi: 10.1016/j.ccr.2012.08.027.
8
Surface immunoglobulin positive lymphoblastic leukemia in adults; a genetic spectrum.成人表面免疫球蛋白阳性淋巴细胞白血病；遗传谱系
Leuk Lymphoma. 2006 Jul;47(7):1352-9. doi: 10.1080/10428190500473238.
9
Childhood pre-B cell acute lymphoblastic leukemia with translocation t(1;19)(q21.1;p13.3) and two additional chromosomal aberrations involving chromosomes 1, 6, and 13: a case report.伴有t(1;19)(q21.1;p13.3)易位及涉及1号、6号和13号染色体的另外两种染色体畸变的儿童前B细胞急性淋巴细胞白血病：一例报告
J Med Case Rep. 2017 Apr 7;11(1):94. doi: 10.1186/s13256-017-1251-1.
10
Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3) translocation.伴有MLL-ENL融合及t(11;19)(q23;p13.3)易位的儿童急性淋巴细胞白血病
J Clin Oncol. 1999 Jan;17(1):191-6. doi: 10.1200/JCO.1999.17.1.191.
引用本文的文献
1
Nanotechnology boosts the efficiency of tumor diagnosis and therapy.纳米技术提高了肿瘤诊断和治疗的效率。
Front Bioeng Biotechnol. 2023 Jul 28;11:1249875. doi: 10.3389/fbioe.2023.1249875. eCollection 2023.
本文引用的文献
1
PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia.蛋白磷酸酶 2A 通过 c-Myc/p21 轴是人类和小鼠急性髓系白血病中具有治疗潜力的细胞命运决定的驱动因素。
Blood. 2022 Mar 3;139(9):1340-1358. doi: 10.1182/blood.2020010344.
2
The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia.ROR1 抗体偶联药物 huXBR1-402-G5-PNU 能够有效靶向 ROR1+白血病。
Blood Adv. 2021 Aug 24;5(16):3152-3162. doi: 10.1182/bloodadvances.2020003276.
3
Clinical features and prognostic impact of TCF3-PBX1 in childhood acute lymphoblastic leukemia: A single-center retrospective study of 837 patients from China.中国单中心 837 例儿童急性淋巴细胞白血病患者中 TCF3-PBX1 的临床特征及预后影响：一项回顾性研究。
Curr Probl Cancer. 2021 Dec;45(6):100758. doi: 10.1016/j.currproblcancer.2021.100758. Epub 2021 May 16.
4
Pharmacokinetics and Tolerability of the Novel Non-immunosuppressive Fingolimod Derivative, OSU-2S, in Dogs and Comparisons with Data in Mice and Rats.新型非免疫抑制性芬戈莫德衍生物 OSU-2S 在犬中的药代动力学和耐受性研究及其与小鼠和大鼠数据的比较。
AAPS J. 2020 Jul 16;22(4):92. doi: 10.1208/s12248-020-00474-9.
5
ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model.ROR1 靶向递送 miR-29b 在体内诱导 CLL 小鼠模型中的细胞周期停滞和治疗获益。
Blood. 2019 Aug 1;134(5):432-444. doi: 10.1182/blood.2018882290. Epub 2019 May 31.
6
Clinical translation of immunoliposomes for cancer therapy: recent perspectives.免疫脂质体用于癌症治疗的临床转化：最新观点。
Expert Opin Drug Deliv. 2018 Sep;15(9):893-903. doi: 10.1080/17425247.2018.1517747. Epub 2018 Sep 12.
7
Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia.I 期临床试验：西仑吉肽抑制慢性淋巴细胞白血病患者的 ROR1 信号和干性特征。
Cell Stem Cell. 2018 Jun 1;22(6):951-959.e3. doi: 10.1016/j.stem.2018.05.018.
8
Acute lymphoblastic leukemia: a comprehensive review and 2017 update.急性淋巴细胞白血病：全面综述及2017年更新
Blood Cancer J. 2017 Jun 30;7(6):e577. doi: 10.1038/bcj.2017.53.
9
Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia.肿瘤抗原ROR1靶向药物递送介导慢性淋巴细胞白血病中白血病B细胞而非正常B细胞的选择性细胞毒性。
Leukemia. 2015 Feb;29(2):346-55. doi: 10.1038/leu.2014.199. Epub 2014 Jun 20.
10
Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia.ROR1 与前 B 细胞受体的串扰促进 t(1;19) 急性淋巴细胞白血病的存活。
Cancer Cell. 2012 Nov 13;22(5):656-67. doi: 10.1016/j.ccr.2012.08.027.
Zotero 插件